Enanta Pharmaceuticals, Inc.
ENTA
$8.68
$0.030.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 64.81M | 64.46M | 66.59M | 67.64M | 71.96M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 64.81M | 64.46M | 66.59M | 67.64M | 71.96M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 64.81M | 64.46M | 66.59M | 67.64M | 71.96M |
| SG&A Expenses | 47.91M | 51.33M | 54.18M | 57.85M | 57.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 161.62M | 166.57M | 176.94M | 189.33M | 194.83M |
| Operating Income | -96.82M | -102.11M | -110.35M | -121.69M | -122.87M |
| Income Before Tax | -94.07M | -98.89M | -106.47M | -117.79M | -118.12M |
| Income Tax Expenses | -2.06M | -2.48M | -1.54M | -1.74M | -2.79M |
| Earnings from Continuing Operations | -92.01 | -96.42 | -104.93 | -116.05 | -115.33 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -92.01M | -96.42M | -104.93M | -116.05M | -115.33M |
| EBIT | -96.82M | -102.11M | -110.35M | -121.69M | -122.87M |
| EBITDA | -93.04M | -98.94M | -107.77M | -119.36M | -120.34M |
| EPS Basic | -4.32 | -4.54 | -4.95 | -5.49 | -5.46 |
| Normalized Basic EPS | -2.78 | -2.93 | -3.16 | -3.51 | -3.57 |
| EPS Diluted | -4.32 | -4.54 | -4.95 | -5.49 | -5.46 |
| Normalized Diluted EPS | -2.78 | -2.93 | -3.16 | -3.51 | -3.57 |
| Average Basic Shares Outstanding | 85.16M | 84.96M | 84.78M | 84.63M | 84.49M |
| Average Diluted Shares Outstanding | 85.16M | 84.96M | 84.78M | 84.63M | 84.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |